Combination therapy of dyslipidemia in non–insulin-dependent diabetes mellitus and the metabolic syndrome
- 42 Downloads
Non–insulin-dependent diabetes mellitus (NIDDM) and the metabolic syndrome separately and additively increase the risk for atherosclerotic cardiovascular disease. Considering the high cardiovascular risk associated with NIDDM and the metabolic syndrome, aggressive therapy of dyslipidemia with tailored combination therapy should be considered given informed consent and discussion of risks. In addition to statins, niacin, and fibrates, therapies shown to decrease the risk for atherosclerotic cardiovascular disease include omega-3 fatty acids, diet, exercise, and optimal blood pressure control with thiazides and blockers of the renin-angiotensin system. These therapies should also be considered to reduce the high cardiovascular risk associated with NIDDM and the metabolic syndrome.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683–689. Diagnosis of the metabolic syndrome is just as important in predicting risk as the diagnosis of NIDDM. Each carries an additive risk for cardiovascular events.PubMedCrossRefGoogle Scholar
- 3.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.CrossRefGoogle Scholar
- 12.Sever PS, Dahlof B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149–1158.PubMedCrossRefGoogle Scholar
- 17.Clofibrate and niacin in coronary heart disease [no authors listed]. JAMA 1975, 231:360–381.Google Scholar
- 21.Zhao XQ, Yuan C, Hatsukami TS, et al.: Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 2001, 21:1623–1629. Combination antidyslipidemic therapy changes the characteristic of the arterial wall, reducing plaque lipid. This may explain the reduction in cardiovascular events.PubMedGoogle Scholar
- 28.Singh RB, Dubnov G, Niaz MA, et al.: Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. Lancet 2002, 360:1455–1461. A Mediterranean diet reduced cardiovascular events and improved the metabolic syndrome.PubMedCrossRefGoogle Scholar